Molecular mass: 279.376 g/mol PubChem compound: 667468
Doxepin is not a central nervous system stimulant nor a monoamine oxidase inhibitor. The current hypothesis is that the clinical effects are due, at least in part, to influences on the adrenergic activity at the synapses so that deactivation of noradrenaline by reuptake into the nerve terminals is prevented.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D04AX01 | D Dermatologicals → D04 Antipruritics, incl. antihistamines, anesthetics, etc. → D04A Antipruritics, incl. antihistamines, anesthetics, etc. → D04AX Other antipruritics | |
| N06AA12 | Doxepin | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AA Non-selective monoamine reuptake inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SILENOR Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| SINEPIN Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Doxepin is an active ingredient of these brands:
United States (US)Australia (AU)
France (FR)
Hong Kong (HK)
Israel (IL)
Mexico (MX)
New Zealand (NZ)
South Africa (ZA)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
